Trinity Biotech (Trinity Biotech) Long-Term Capital Lease Obligation : $10.92 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Long-Term Capital Lease Obligation?

Trinity Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $10.92 Mil.

Trinity Biotech's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 ($12.03 Mil) to Jun. 2023 ($11.55 Mil) and declined from Jun. 2023 ($11.55 Mil) to Sep. 2023 ($10.92 Mil).

Trinity Biotech's annual Long-Term Capital Lease Obligation declined from Dec. 2020 ($16.59 Mil) to Dec. 2021 ($13.87 Mil) and declined from Dec. 2021 ($13.87 Mil) to Dec. 2022 ($12.27 Mil).

Trinity Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Trinity Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Long-Term Capital Lease Obligation Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.53

17.75

16.59

13.87

12.27

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	12.27	12.03	11.55	10.92

Trinity Biotech (NAS:TRIB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Trinity Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.